Journal for Immunotherapy of Cancer

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	233
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	190
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	187
Commentary on oncolytic viruses: past, present, and future	178
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	163
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	152
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	147
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	143
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	136
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	135
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	131
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	131
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	129
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	126
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	124
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	123
Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	116
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	115
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	112
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	112
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	111
T-cell tolerant fraction as a predictor of immune-related adverse events	110
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	107
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	105
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	103

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphoma	101
Single-cell analysis reveals clonally expanded tumor-associated CD57+CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	100
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	100
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	98
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	96
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	96
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	91
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	91
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	90
iRECIST and atypical patterns of response to immuno-oncology drugs	90
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	89
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	88
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	88
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	87
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	85
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	84
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	83
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	80
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	79
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	79
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	78
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	78
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	77
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	75
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	74
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	73
Is immunotherapy safe and effective in patients with VEXAS syndrome?	73
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes	72
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	72
Biomarkers for response to TIL therapy: a comprehensive review	72
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	71
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	71
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	70
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	70
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	70
Modulating lipid metabolism improves tumor immunotherapy	68
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	67
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	67
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	66
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	66
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	65
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	65
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	64
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	64
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	64
Addendum 1:Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	64
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	64
Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth	64
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	63

Poor clinical outcomes and immunoevasive contexture in CD161+CD8+T cells barren human pancreatic cancer	63
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	63
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	62
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	62
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	62
11 Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents	60
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	60
Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	59
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	59
Correction: Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer	59
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	58
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	58
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+T cell-dependent antitumor immunity and abscopal effect after local irradiation	58
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	58
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	58
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer	56
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	56
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	56
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	55
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses	55
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	55
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	55
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications	55
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	55
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	55
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	55
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	55
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy	54
Apoptosis: aJanus bifronsin T-cell immunotherapy	54
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	54
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	54
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	54
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers	54
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade	54
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+T cell cytotoxicity over BEMPEG+RT	54
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer	54
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	54
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	53
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	53
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	53
Accumulation of T-cell-suppressive PD-L1highextracellular vesicles is associated with GvHD and might impact GvL efficacy	53
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer	53
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	53
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation	53
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	53
Sulforaphane activates CD8+T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	52
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis	52
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	52
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	52
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes	52
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer	52
PD-L1 gene amplification and focality: relationship with protein expression	52
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	52
Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer	51
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	51
Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study	51
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types	51
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	50
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	50
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma	50
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)	50
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	50
Id-neoantigen vaccine induces therapeutic CD8+T cells against multiple myeloma: H chain-loss escapees cause FLC MM	50
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	50
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	50
20 Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy	49
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	49
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	49
36 Digital Whole Slide Image (WSI) scoring is equivalent to microscope glass slide scoring for evaluation of programmed death-ligand 1 (PD-L1) expression across multiple tumor indications	49
Correction: Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?	49
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	49
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	49
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	49
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	49
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	48
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex	48
291 Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity	48
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer	48
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	48
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	48

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors	48
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer	48
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+T cell and XCR1+dendritic cell spatial co-localization	47
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	47
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	47
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies	47
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	47
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	46
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	46
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer	46
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy	46
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	46
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	45
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	45
322 Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment	45
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	45
19 Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST	45
Correction: Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy	45
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	44
45 AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells	44
Rescuing natural killer cells from the cancer wilderness	44
Guidelines for immunological analyses following focused ultrasound treatment	44
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	44
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity	44
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	44
52 Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI)	44
Neoantigens as potential vaccines in hepatocellular carcinoma	44
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome	44
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	43
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	43
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	43
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	43
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	43
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis	43
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models	43
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)	43
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling	43
Serotonin receptor 5-HT2Aas a potential target for HCC immunotherapy	42
Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer	42
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients withBRAFV600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)	42
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade	42
Potentiation of cancer immunogenicity by targeting PARP	42
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	42
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	42
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression	42
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	42
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma	42
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	42
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	42
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	41
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	41
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	41
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade	41
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	41
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy	41
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy	41
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial	41
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chhedaet al	41
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma	40
212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates	40
Correction: MRI techniques for immunotherapy monitoring	40
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	40
292 Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in solid tumors	40
Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	40
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	40
64 A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains	40
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	39
318 Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance	39
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	39
Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice	39
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia	39
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	39
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases	39
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	39
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	39
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression	39
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	39
Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer	39
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin	39
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies	39
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	38
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins	38
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas	38
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors	38
Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells	38
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy	38
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells	38
Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis	38
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer	38
Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression	38
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis	37
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release	37
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis	37
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS	37
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma	37